Literature DB >> 17511586

Clinical perspective of hypoxia-mediated pulmonary hypertension.

Ioana R Preston1.   

Abstract

Pulmonary hypertension is a condition associated with a variety of pulmonary disorders whose common denominator is alveolar hypoxia. Such disorders include chronic obstructive pulmonary disease, pulmonary fibrosis, sleep-disordered breathing, and exposure to high altitude. Acute hypoxia is characterized by vasoconstriction of small pulmonary arteries, a phenomenon called hypoxic pulmonary vasoconstriction. With prolonged hypoxia, thickening of the smooth vascular layer of the small pulmonary arteries occurs, a phenomenon described as pulmonary vascular remodeling. Although the core mechanisms of both vasoconstriction and remodeling are thought to reside in the smooth muscle cell layer, the endothelium modulates these two processes. The purpose of this review is briefly to (a) discuss the mechanisms of hypoxic pulmonary hypertension as it pertains to certain disease states, and (b) examine the pathways that have potential therapeutic applications for this condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17511586     DOI: 10.1089/ars.2007.1587

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  16 in total

Review 1.  Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology.

Authors:  Cyrus Kholdani; Wassim H Fares; Vahid Mohsenin
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

2.  Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease.

Authors:  Marilee J Wick; Erica J Buesing; Carol A Wehling; Zoe L Loomis; Carlyne D Cool; Martin R Zamora; York E Miller; Sean P Colgan; Louis B Hersh; Norbert F Voelkel; Edward C Dempsey
Journal:  Am J Respir Crit Care Med       Date:  2010-09-02       Impact factor: 21.405

Review 3.  The emerging role of microRNAs in hypoxia-induced pulmonary hypertension.

Authors:  Vahid Mohsenin
Journal:  Sleep Breath       Date:  2016-05-07       Impact factor: 2.816

4.  Hypoxic upregulation of arginase II in human lung endothelial cells.

Authors:  Karina Krotova; Jawaharlal M Patel; Edward R Block; Sergey Zharikov
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

5.  Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases.

Authors:  Jianliang Zhang; Jawaharlal M Patel
Journal:  Int J Clin Exp Med       Date:  2010-08-10

6.  The effects of vasoactivity and hypoxic pulmonary hypertension on extralobar pulmonary artery biomechanics.

Authors:  Diana M Tabima; Naomi C Chesler
Journal:  J Biomech       Date:  2010-04-22       Impact factor: 2.712

7.  Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation.

Authors:  Caterina P Minniti; Craig Sable; Andrew Campbell; Sohail Rana; Gregory Ensing; Niti Dham; Onyinye Onyekwere; Mehdi Nouraie; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

8.  Collagen-related gene and protein expression changes in the lung in response to chronic hypoxia.

Authors:  Kristine D Estrada; Naomi C Chesler
Journal:  Biomech Model Mechanobiol       Date:  2008-07-20

Review 9.  Hypoxic pulmonary vasoconstriction in humans.

Authors:  Priyadharshanan Ariyaratnam; Mahmoud Loubani; Alyn H Morice
Journal:  Biomed Res Int       Date:  2013-08-20       Impact factor: 3.411

10.  Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.

Authors:  Xiaomei Niu; Mehdi Nouraie; Andrew Campbell; Sohail Rana; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; N Scott Reading; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.